title: Choice of treatment affects plasma levels of insulin-like growth factor-binding protein-1 in noninsulin-dependent diabetes mellitus.
abstract: Insulin-like growth factor (IGF)-binding protein-1 (IGFBP-1) modulates the metabolic and mitogenic effects of IGFs. Although IGFBP-1 levels are abnormally high in insulin-dependent diabetes (IDDM), relatively little is known in NIDDM; conflicting data have suggested both high and low levels. We investigated whether treatment modifies IGFBP-1 levels in two groups of NIDDM patients. Study 1 examined fasting concentrations in groups of patients with NIDDM, comparable except for treatment type (sulfonylurea, n = 23; once daily insulin, n = 15; sulfonylurea plus once daily insulin, n = 14; multiple insulin injections, n = 9) and 25 nondiabetic subjects. In sulfonylurea-treated patients there were markedly reduced plasma IGFBP-1 concentrations (median, interquartile range in parentheses): control, 61.0 (36-96) micrograms/L; sulfonylureas alone, 31.5 (21-61) micrograms/L (P < 0.01); and sulfonylureas plus insulin, 31.5 (9-53) micrograms/L (P < 0.01). Once daily insulin was associated with values similar to those in the control group [62.0 (27-103) micrograms/L; P = NS], whereas IGFBP-1 levels were higher with multiple insulin injection therapy [156.0 (71-184) micrograms/L; P < 0.05]. Proinsulin levels were higher in sulfonylurea-treated patients, but there was no significant correlation between IGFBP-1 and proinsulin within any individual group. Study 2 examined the effects of treatment on the dynamics of IGFBP-1 levels between 0800-1900 h. In control subjects (n = 8), levels fell from 0800 h (mean +/- SEM, 22.4 +/- 5.2 micrograms/L) to 1000 h (14 +/- 5.2 micrograms/L), followed by a rise, more rapid after food, to a peak at 1240 h (20.6 +/- 3.7 micrograms/L). Levels then declined until 1500 h (10.7 +/- 2.9 micrograms/L), with a further postprandial peak at 1840 h (23.1 +/- 3.2 micrograms/L). Sulfonylurea therapy (n = 6) resulted in a complete loss of this pattern, with a marked fall in IGFBP-1 from 0800 h (22 +/- 2.7 micrograms/L) to less than 7 micrograms/L for the remainder of the study (area under the curve, 1150-1400 h, P < 0.001 vs. control). By contrast, in metformin-treated patients (n = 7), neither IGFBP-1 levels nor postprandial peaks were significantly different from those in the control group. Our findings suggest that in patients with NIDDM, the regulation of IGFBP-1 is markedly influenced by the choice of treatment.
authors.affiliation: University of Manchester, Department of Medicine, Hope Hospital, Salford, United Kingdom.
authors.forename: J M
authors.initials: JM
authors.lastname: Gibson
authors.forename: M
authors.initials: M
authors.lastname: Westwood
authors.forename: S R
authors.initials: SR
authors.lastname: Crosby
authors.forename: C
authors.initials: C
authors.lastname: Gordon
authors.forename: J M
authors.initials: JM
authors.lastname: Holly
authors.forename: W
authors.initials: W
authors.lastname: Fraser
authors.forename: C
authors.initials: C
authors.lastname: Anderson
authors.forename: A
authors.initials: A
authors.lastname: White
authors.forename: R J
authors.initials: RJ
authors.lastname: Young
mesh_terms: D002352:Carrier Proteins / Q000097:blood*; D002940:Circadian Rhythm; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005215:Fasting; D005260:Female; D006801:Humans; D007328:Insulin / Q000627:therapeutic use*; D018970:Insulin-Like Growth Factor Binding Protein 1; D008297:Male; D008687:Metformin / Q000627:therapeutic use*; D008875:Middle Aged; D011384:Proinsulin / Q000097:blood; D012016:Reference Values; D013002:Somatomedins / Q000378:metabolism; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*
chemical_list: D002352:Carrier Proteins; D007328:Insulin; D018970:Insulin-Like Growth Factor Binding Protein 1; D013002:Somatomedins; D013453:Sulfonylurea Compounds; D011384:Proinsulin; D008687:Metformin